Cardiff Oncology, Inc.
CRDFNASDAQHealthcare● Active
$1.50
+$0.00(+0.00%)
Market Cap$102554844
P/E Ratio—
52W High$4.56
52W Low$1.35
Cardiff Oncology, Inc. (CRDF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CRDF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.59M | $0.68M | $0.49M | $0.39M | $0.36M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.59M | $0.68M | $0.49M | $0.39M | $0.36M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $35.33M | $36.85M | $32.86M | $27.11M | $17.38M |
| G&A Expenses | $14.22M | $12.48M | $13.04M | $13.18M | $11.84M |
| Total Operating Expenses | $49.55M | $49.33M | $45.90M | $40.29M | $29.21M |
| Operating Income | ($48.96M) | ($48.65M) | ($45.41M) | ($39.90M) | ($28.86M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $3.10M | $3.26M | $4.07M | $1.58M | $0.26M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($45.85M) | ($45.43M) | ($41.44M) | ($38.70M) | ($28.29M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($45.85M) | ($45.43M) | ($41.44M) | ($38.70M) | ($28.29M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 |
| Wtd Avg Shares | 66.84M | 47.65M | 44.68M | 43.60M | 39.03M |
| EBITDA | ($48.06M) | ($48.25M) | ($45.01M) | ($39.67M) | ($28.40M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Cardiff Oncology, Inc. data
About Cardiff Oncology, Inc. (CRDF) Income Statement
Cardiff Oncology, Inc. (CRDF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CRDF reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.05B) — a net profit margin of -7732.04%.
Frequently asked questions
CRDF · 4 questionsCardiff Oncology, Inc. (CRDF) reported revenue of $0.00B for 2025, down 13.2% year-over-year.
CRDF revenueCRDF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09